|
|
Engages in the research, production and distribution of pharmaceutical productsSanofi engages in the research, production and distribution of pharmaceutical products. The company operates through the following segments: Pharmaceuticals, Human Vaccines and Animal Health. The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products. This segment also includes equity affiliates and joint ventures with pharmaceutical business activities. The Human Vaccines segment includes research, development, production and marketing. The Animal Health segment comprises the research, development, production and marketing activities for vaccines. It offers a range of medicines and vaccines on animal species. The company was founded in 1994 and is headquartered in Paris, France.
|
|
|
|
| 2012 | 2013 | Delta | | USD (in Million) | % | USD (in Million) | % | | Pharmaceuticals | 37,294 | 82.6% | 36,247 | 82.7% | -2.89% | | Vaccines | 5,034 | 11.2% | 4,943 | 11.3% | -1.84% | | Animal Health | 2,815 | 6.2% | 2,640 | 6% | -6.6% |
|
|
|
| 2012 | 2013 | Delta | | USD (in Million) | % | USD (in Million) | % | | Rest of the World | 16,084 | 35.6% | 15,219 | 34.7% | -5.68% | | United States | 14,045 | 31.1% | 13,878 | 31.7% | -1.21% | | Europe | 10,605 | 23.5% | 10,552 | 24.1% | -0.5% | | France | 3,676 | 8.1% | 3,420 | 7.8% | -7.5% | | North America | 732.42 | 1.6% | 762.19 | 1.7% | +3.91% |
|
|
|
| Name | Age | Officer Since | Title | | Christopher A. Viehbacher, CPA | 54 | 2008 | Chief Executive Officer & Director | | Serge Weinberg | 63 | 2009 | Chairman | | Jérôme Contamine | 56 | 2009 | Chief Financial Officer & Executive Vice President | | Elias Adam E. Zerhouni, MD | 63 | 2010 | President-Global Research & Development | | Bruno Ménard | - | 2011 | Chief Information Officer | | Jorge Insuasty, MD | - | 2011 | VP, Deputy President-Research & Development | | Ji Zhang, PhD | - | 2003 | Head-Research & Development Scientific Platforms | | Gary J. Nabel MD, PhD | - | 2012 | Chief Scientific Officer & Senior Vice President | | Paul Chew, PhD | - | 2013 | Chief Medical Officer & Senior Vice President | | Igor Landau, MBA | 70 | 2004 | Member-Supervisory Board |
|
| Surperformance© rating of Sanofi SA | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
|
|
|
| Investor Rating |
|
|
|
| Growth (Revenue) |
|
|
|
| Valuation |
|
|
|
| Finances |
|
|
|
| Profitability |
|
|
|
| Earnings quality |
|
|
|
| Business Predictability |
|
|
|
| PER |
|
|
|
| Potential |
|
|
|
| Yield |
|
|
|
| Consensus |
|
|
|
| 7 days EPS revision |
|
|
|
| 4 months EPS revision |
|
|
|
| 1 year EPS revision |
|
|
|
| 4 months Revenue revision |
|
|
|
| 1 year Revenue revision |
|
|
|
| |
|
|
|
|
| Company contact information |
|
Sanofi
54, rue La Boétie
8ème arrondissement
Paris, Ile-de-France 75008
Phone : +33.1.53.77.40.00
Fax : +33.1.53.77.43.03
Web : www.sanofi.com
|
© 2014 Factset 
|
|
